These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36314883)

  • 21. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
    Tang LQ; Chen QY; Fan W; Liu H; Zhang L; Guo L; Luo DH; Huang PY; Zhang X; Lin XP; Mo YX; Liu LZ; Mo HY; Li J; Zou RH; Cao Y; Xiang YQ; Qiu F; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Mai HQ
    J Clin Oncol; 2013 Aug; 31(23):2861-9. PubMed ID: 23857969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification:
    Ng WT; Chua MLK; Lee AWM
    J Clin Oncol; 2022 Apr; 40(11):1135-1138. PubMed ID: 35213233
    [No Abstract]   [Full Text] [Related]  

  • 24. The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Wan Y; Tian L; Zhang G; Xin H; Li H; Dong A; Liang Y; Jing B; Zhou J; Cui C; Chen M; Sun Y; Xie C; Liu L; Shao Y
    Radiother Oncol; 2019 Feb; 131():35-44. PubMed ID: 30773185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synchronous occurrence of nasopharyngeal carcinoma and Hodgkin lymphoma.
    Stokken J; Manz RM; Flagg A; Kate Gowans L; Anne S
    Int J Pediatr Otorhinolaryngol; 2014 Jan; 78(1):154-6. PubMed ID: 24290306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal carcinoma.
    Yap YY; Hassan S; Chan M; Choo PK; Ravichandran M
    Otolaryngol Head Neck Surg; 2007 Jun; 136(6):986-91. PubMed ID: 17547993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of Epstein-Barr virus in metastatic lymph nodes of patients with nasopharyngeal carcinoma and a primary unknown carcinoma.
    Nakao K; Yuge T; Mochiki M; Nibu K; Sugasawa M
    Arch Otolaryngol Head Neck Surg; 2003 Mar; 129(3):338-40. PubMed ID: 12622545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
    Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of Epstein-Barr virus DNA in formalin-fixed paraffin-embedded tissue of nasopharyngeal carcinoma using polymerase chain reaction and in situ hybridization.
    Akao I; Sato Y; Mukai K; Uhara H; Furuya S; Hoshikawa T; Shimosato Y; Takeyama I
    Laryngoscope; 1991 Mar; 101(3):279-83. PubMed ID: 1847985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus: the path from association to causality for a ubiquitous human pathogen.
    Sugden B
    PLoS Biol; 2014 Sep; 12(9):e1001939. PubMed ID: 25180782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
    Topkan E; Somay E; Selek U; Pehlivan B
    Eur J Cancer; 2024 Mar; 200():113459. PubMed ID: 38057215
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial.
    Liu X; Guo L; Xie FY; Hu WH; Chen MY; He QM; Xu ZM; Zhang CQ; Peng YL; Tang LL; Mao YP; Sun R; Li JB; Argiris A; Hui EP; Sun Y; Ma J
    Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1063-1071. PubMed ID: 35550406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.
    Liu X; Deng Y; Huang Y; Ye J; Xie S; He Q; Chen Y; Lin Y; Liang R; Wei J; Li Y; Zhang J
    Curr Oncol; 2022 Aug; 29(9):6035-6052. PubMed ID: 36135044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
    Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
    Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.